Trexquant Investment LP Sells 20,677 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Trexquant Investment LP trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 21.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 74,275 shares of the specialty pharmaceutical company's stock after selling 20,677 shares during the quarter. Trexquant Investment LP owned about 0.13% of Supernus Pharmaceuticals worth $2,686,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its position in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $52,000. Headlands Technologies LLC increased its holdings in shares of Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 1,015 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $72,000. Finally, Venturi Wealth Management LLC bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth $92,000.

Analysts Set New Price Targets

SUPN has been the topic of several research reports. StockNews.com downgraded shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Remove Ads

Insiders Place Their Bets

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,104 shares of company stock valued at $440,263. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Trading Up 1.9 %

Shares of SUPN stock traded up $0.60 during trading on Friday, hitting $31.67. The company's stock had a trading volume of 407,129 shares, compared to its average volume of 492,037. The company has a market cap of $1.77 billion, a PE ratio of 29.60 and a beta of 0.90. The business has a fifty day moving average of $33.52 and a 200-day moving average of $35.04. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.